Luo Li

Chongqing, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

The AUTACE That Degrades KRAS and Engages CD8+ T Cells for the Treatment of KRAS/TP53 Co-Mutant Tumors.

The AUTACE That Degrades KRAS and Engages CD8+ T Cells for the Treatment of KRAS/TP53 Co-Mutant Tumors.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: September 19, 2025

Therapeutic potential of T-cell receptor targeting the HLA-A*11:01-restricted KRASG12V neoantigen without cross-recognition of the self-antigen RAB7B in solid tumors.

Therapeutic potential of T-cell receptor targeting the HLA-A*11:01-restricted KRASG12V neoantigen without cross-recognition of the self-antigen RAB7B in solid tumors.

Journal: Journal for immunotherapy of cancer
Published: July 02, 2025

PCK1 deficiency promotes MASH-HCC progression by 12-HETE-induced CD8+ T cell dysfunction.

PCK1 deficiency promotes MASH-HCC progression by 12-HETE-induced CD8+ T cell dysfunction.

Journal: Gut
Published: December 10, 2024

Identification of novel KRASG12D neoantigen specific TCRs and a strategy to eliminate off-target recognition.

Identification of novel KRASG12D neoantigen specific TCRs and a strategy to eliminate off-target recognition.

Journal: Journal of translational medicine
Published: October 08, 2024

Targeting tumor-infiltrating CCR8+ regulatory T cells induces antitumor immunity through functional restoration of CD4+ Tconvs and CD8+ T cells in colorectal cancer.

Targeting tumor-infiltrating CCR8+ regulatory T cells induces antitumor immunity through functional restoration of CD4+ Tconvs and CD8+ T cells in colorectal cancer.

Journal: Journal of translational medicine
Published: May 12, 2024

Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations.

Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations.

Journal: Cancer immunology, immunotherapy : CII
Published: April 10, 2024

A Highly Conserved Peptide Vaccine Candidate Activates Both Humoral and Cellular Immunity Against SARS-CoV-2 Variant Strains.

A Highly Conserved Peptide Vaccine Candidate Activates Both Humoral and Cellular Immunity Against SARS-CoV-2 Variant Strains.

Journal: Frontiers in immunology
Published: October 05, 2021

Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants.

Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants.

Journal: Nature communications
Published: June 12, 2021

p38 inhibition enhances TCR-T cell function and antagonizes the immunosuppressive activity of TGF-β.

p38 inhibition enhances TCR-T cell function and antagonizes the immunosuppressive activity of TGF-β.

Journal: International immunopharmacology
Published: April 29, 2021

T Cell Immunity Evaluation and Immunodominant Epitope T Cell Receptor Identification of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Glycoprotein in COVID-19 Convalescent Patients.

T Cell Immunity Evaluation and Immunodominant Epitope T Cell Receptor Identification of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Glycoprotein in COVID-19 Convalescent Patients.

Journal: Frontiers in cell and developmental biology
Published: April 17, 2021

A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2.

A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2.

Journal: Frontiers in immunology
Published: January 14, 2021

HepaCAM Regulates Warburg Effect of Renal Cell Carcinoma via HIF-1α/NF-κB Signaling Pathway.

HepaCAM Regulates Warburg Effect of Renal Cell Carcinoma via HIF-1α/NF-κB Signaling Pathway.

Journal: Urology
Published: September 20, 2018
Showing 1-12 of 12

Last Updated: 09/26/2026